Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 juil. 2019 07h00 HE | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%

VANCOUVER, British Columbia, July 29, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
04 avr. 2019 07h00 HE | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board

VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
09 oct. 2018 07h00 HE | Source: Breathtec Biomedical Inc.

Breathtec Announces Signing of Definitive Agreement to Acquire Nash Pharmaceuticals

VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”) is pleased to announce...